KRAS Testing

We deliver a fast, simple KRAS service with secure online reporting.

  • 2-4 days turnaround time from sample receipt 
  • Secure delivery of electronic reports
  • Macro-dissection to increase tumour burden
  • Combined KRAS & BRAF testing available
  • CPA accreditation
  • Simple request form           

Our KRAS testing service is FREE for all NHS samples

Just complete a request form and post your specimen and completed form to us, and we'll do the rest. Our SPA (Secure Portal Access) system will quickly and securely deliver electronic reports to you within 2-4 days receipt of the specimens.

For further information contact our us +44 (0)115 973 9012 or email sales@sourcebioscience.com

KRAS testing - more information

Key Facts

  • KRAS protein is an important signalling intermediate in the EGFR pathway
  • Three activating mutations of the KRAS gene are known to occur, at codons 12,13, and 61
  • KRAS mutations are relatively common in colorectal and lung cancers
  • The presence of a KRAS mutation suggests a patient is unlikely to respond to EGFR-targeted treatment

In different cancer types, in particular those of colorectum and lung, certain subsets of patients have been shown to benefit from anti-EGFR therapies; however a significant proportion show no benefit from these agents. The KRAS gene encodes a protein that plays a key role in transmitting the original signal from EGFR downstream to activate important cell functions, in particular proliferation and survival.

Acquired mutations of this gene commonly occur in pancreatic, colorectal and lung tumours. These mutations are activating, leading to uncontrolled signalling. They occur primarily in one small region of the gene and make tumours resistant to anti-EGFR therapies. Patients with such mutations in their tumours are therefore considered unlikely to benefit from anti-EGFR therapies. Current guidelines in the US and Europe suggest that all patients being considered for such therapies should be tested for KRAS mutations.

We offer KRAS mutation testing suitable for archival FFPE tissue samples:

  • For routine samples,  pyrosequencing  is performed on the Qiagen/Biotage PyroMark™ system, which detects activating mutations in codons 12, 13 and 61 of the KRAS gene

These mutations are associated with resistance to the anti-EGFR monoclonal antibody therapeutics cetuximab (Erbitux™) and panitumumab (Vectibix™), and the small molecule inhibitors of EGFR gefitinib (Iressa™) and erlotinib (Tarceva™). The results of mutation tests are reported as positive or negative for the presence of a particular mutation, along with additional information about relative frequencies of particular mutations in colorectal and lung tumours.

Further information:

Mutations:

Mutations are identified against the NCBI reference sequence (RefSeq ID : NM_033360)

Amino acid change

Nucleic acid change

 

Amino acid change

Nucleic acid change

p.Gly12Asp

c.35G>A

 

p.Gln61His

c.183A>C

p.Gly12Val

c.35G>T

 

p.Gln61His

c.183A>T

p.Gly12Cys

c.34G>T

 

 

 

p.Gly12Ala

c.35G>C

 

 

 

p.Gly12Ser

c.34G>A

 

 

 

p.Gly12Arg

c.34G>C

 

 

 

p.Gly13Asp

c.38G>A

 

 

 

Mutations are reported as per the internationally recognised Human Genome Variation Society format where p.Gly12Asp refers to an amino acid change at codon 12 from Gly to Asp and c.35G>A refers to a nucleic acid change at position 35 from G to A.

References:

National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer. Published online November 2008. http://www.nccn.org/about/news/newsinfo.asp?NewsID=194

van Krieken et al. (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453:417